Literature DB >> 9617783

The effects of acute phencyclidine treatment on neuropeptide Y (NPY) neuronal system in the rat arcuate nucleus studied by immunocytochemistry and in situ hybridization.

K Fukui1, Y Kawashima, H Iizumi, H Utsumi, T Nakajima.   

Abstract

Phencyclidine (PCP) is a dissociative drug and an antagonist of N-methyl-D-aspartate (NMDA) receptor. The effects of PCP treatment on neuropeptide Y (NPY) system in the arcuate nucleus of the rat hypothalamus were examined both by immunocytochemistry and in situ hybridization. In acute PCP-treated rats, the NPY-immunoreactive perikarya appeared in the arcuate nucleus but no perikarya were detected in controls, without colchicine pretreatment. The signals of NPY mRNA by in situ hybridization increased in the PCP-treated rats than those of controls. These results suggest that the NPY system in the arcuate nucleus might be partly controlled by glutamatergic neurons.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9617783     DOI： 10.1007/BF01276415

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  21 in total

Review 1.  Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential.

Authors:  K M Johnson; S M Jones
Journal:  Annu Rev Pharmacol Toxicol       Date:  1990       Impact factor: 13.820

2.  Effect of haloperidol on immunoreactive neuropeptide Y in rat cerebral cortex and basal ganglia.

Authors:  M Miyake; K Iguchi; H Okamura; K Fukui; T Nakajima; K Chihara; Y Ibata; N Yanaihara
Journal:  Brain Res Bull       Date:  1990-08       Impact factor: 4.077

3.  Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.

Authors:  K Tatemoto; M Carlquist; V Mutt
Journal:  Nature       Date:  1982-04-15       Impact factor: 49.962

4.  Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures.

Authors:  J Peters; D P Van Kammen; J Gelernter; J Yao; D Shaw
Journal:  Schizophr Res       Date:  1990 Oct-Dec       Impact factor: 4.939

5.  Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat.

Authors:  B J Everitt; T Hökfelt; L Terenius; K Tatemoto; V Mutt; M Goldstein
Journal:  Neuroscience       Date:  1984-02       Impact factor: 3.590

6.  A diurnal variation of vasoactive intestinal peptide (VIP) mRNA under a daily light-dark cycle in the rat suprachiasmatic nucleus.

Authors:  S Okamoto; H Okamura; M Miyake; Y Takahashi; S Takagi; Y Akagi; K Fukui; H Okamoto; Y Ibata
Journal:  Histochemistry       Date:  1991

7.  Immunohistochemical alterations in neuropeptide Y-positive nerve elements in rat cerebral cortex following acute phencyclidine treatment.

Authors:  K Fukui; Y Kawashima; H Iizumi; H Utsumi; T Nakajima
Journal:  Neuroreport       Date:  1995-03-07       Impact factor: 1.837

8.  A circadian rhythm of somatostatin messenger RNA levels, but not of vasoactive intestinal polypeptide/peptide histidine isoleucine messenger RNA levels in rat suprachiasmatic nucleus.

Authors:  J Takeuchi; H Nagasaki; K Shinohara; S T Inouye
Journal:  Mol Cell Neurosci       Date:  1992-02       Impact factor: 4.314

9.  Glutamate, the dominant excitatory transmitter in neuroendocrine regulation.

Authors:  A N van den Pol; J P Wuarin; F E Dudek
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

10.  Serotonergic involvement in phencyclidine-induced behaviors.

Authors:  T Nabeshima; K Yamaguchi; M Hiramatsu; M Amano; H Furukawa; T Kameyama
Journal:  Pharmacol Biochem Behav       Date:  1984-09       Impact factor: 3.533
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.